RP105-Negative B Cells in Systemic Lupus Erythematosus
Systemic lupus erythematosus (SLE) is a multisystem disease characterized by B cells producing autoantibodies against nuclear proteins and DNA, especially anti-double-strand DNA (dsDNA) antibodies. RP105 (CD180), the toll-like receptor- (TLR-) associated molecule, is expressed on normal B cells. How...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | Clinical and Developmental Immunology |
| Online Access: | http://dx.doi.org/10.1155/2012/259186 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832558671359377408 |
|---|---|
| author | Syuichi Koarada Yoshifumi Tada |
| author_facet | Syuichi Koarada Yoshifumi Tada |
| author_sort | Syuichi Koarada |
| collection | DOAJ |
| description | Systemic lupus erythematosus (SLE) is a multisystem disease characterized by B cells producing autoantibodies against nuclear proteins and DNA, especially anti-double-strand DNA (dsDNA) antibodies. RP105 (CD180), the toll-like receptor- (TLR-) associated molecule, is expressed on normal B cells. However, RP105-negative B cells increase in peripheral blood from patients with active SLE. RP105 may regulate B-cell activation, and RP105-negative B cells produce autoantibodies and take part in pathophysiology of SLE. It is possible that targeting RP105-negative B cells is one of the treatments of SLE. In this paper, we discuss the RP105 biology and clinical significance in SLE. |
| format | Article |
| id | doaj-art-95651c7034e94d1ab5e1964896b02b8b |
| institution | Kabale University |
| issn | 1740-2522 1740-2530 |
| language | English |
| publishDate | 2012-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Clinical and Developmental Immunology |
| spelling | doaj-art-95651c7034e94d1ab5e1964896b02b8b2025-02-03T01:31:49ZengWileyClinical and Developmental Immunology1740-25221740-25302012-01-01201210.1155/2012/259186259186RP105-Negative B Cells in Systemic Lupus ErythematosusSyuichi Koarada0Yoshifumi Tada1Division of Rheumatology, Faculty of Medicine, Saga University, 5-1-1 Nabeshima, Saga 849-8501, JapanDivision of Rheumatology, Faculty of Medicine, Saga University, 5-1-1 Nabeshima, Saga 849-8501, JapanSystemic lupus erythematosus (SLE) is a multisystem disease characterized by B cells producing autoantibodies against nuclear proteins and DNA, especially anti-double-strand DNA (dsDNA) antibodies. RP105 (CD180), the toll-like receptor- (TLR-) associated molecule, is expressed on normal B cells. However, RP105-negative B cells increase in peripheral blood from patients with active SLE. RP105 may regulate B-cell activation, and RP105-negative B cells produce autoantibodies and take part in pathophysiology of SLE. It is possible that targeting RP105-negative B cells is one of the treatments of SLE. In this paper, we discuss the RP105 biology and clinical significance in SLE.http://dx.doi.org/10.1155/2012/259186 |
| spellingShingle | Syuichi Koarada Yoshifumi Tada RP105-Negative B Cells in Systemic Lupus Erythematosus Clinical and Developmental Immunology |
| title | RP105-Negative B Cells in Systemic Lupus Erythematosus |
| title_full | RP105-Negative B Cells in Systemic Lupus Erythematosus |
| title_fullStr | RP105-Negative B Cells in Systemic Lupus Erythematosus |
| title_full_unstemmed | RP105-Negative B Cells in Systemic Lupus Erythematosus |
| title_short | RP105-Negative B Cells in Systemic Lupus Erythematosus |
| title_sort | rp105 negative b cells in systemic lupus erythematosus |
| url | http://dx.doi.org/10.1155/2012/259186 |
| work_keys_str_mv | AT syuichikoarada rp105negativebcellsinsystemiclupuserythematosus AT yoshifumitada rp105negativebcellsinsystemiclupuserythematosus |